Full interview: Genprex’s newly licensed type 1 diabetes gene therapy’s potential explained by scientist

Dr George Gittes, Professor of Surgery at the Children’s Hospital of Pittsburgh explains how and why he began working on the gene therapy licensed by Genprex (NASDAQ:GNPX).

Dr Gittes says the therapy, currently undergoing pre-clinical studies, has shown data where it caused pancreatic cells to turn into insulin-producing cells.

Watch it here –>

Print Friendly, PDF & Email